Growth Hormone Secretagogues: Complete Guide to CJC-1295, Ipamorelin, Sermorelin & More

Growth Hormone Secretagogues: A Complete Guide to GH-Releasing Peptides and Analogs

Growth hormone secretagogues (GHS) are the largest and most extensively researched category of research peptides. From GHRH analogs like CJC-1295 and Sermorelin to ghrelin receptor agonists like Ipamorelin and Hexarelin, and FDA-approved compounds like Tesamorelin, this guide provides a comprehensive overview of every major GH secretagogue, their mechanisms, and how they compare.

Browse our complete research peptide catalog and visit the research hub for more guides.

The Growth Hormone Axis

Understanding GH secretagogues requires understanding the GH regulatory axis:

1. GHRH (hypothalamus): Growth hormone-releasing hormone is secreted by the hypothalamus to stimulate GH synthesis and release from pituitary somatotrophs
2. Somatostatin (hypothalamus): The inhibitory counterpart — suppresses GH release in a rhythmic pattern, creating the pulsatile GH secretion pattern
3. Ghrelin (stomach): The “hunger hormone” acts on pituitary GHS-R1a receptors to amplify GH release and suppress somatostatin
4. GH (pituitary): Released in pulses, GH acts on the liver and other tissues
5. IGF-1 (liver): GH stimulates hepatic IGF-1 production, which mediates many of GH’s growth and repair effects
6. Negative feedback: Both GH and IGF-1 feed back to suppress GHRH and increase somatostatin, maintaining homeostasis

GHRH Analogs: Stimulating the Signal

CJC-1295 (Modified GRF 1-29)

CJC-1295 is the most popular GHRH analog in research:

• Structure: 29-amino acid GHRH analog with 4 amino acid substitutions (Ala2?D-Ala, Asn8?Gln, Ala15?Ala, Met27?Leu) for improved metabolic stability
• Half-life: ~30 minutes (no DAC version). The DAC (Drug Affinity Complex) version binds albumin, extending half-life to ~8 days
• Key advantage: Stimulates the entire GH cascade (GH + all direct GH effects + IGF-1) with preserved somatostatin feedback
• Best combined with: A GHRP (Ipamorelin) for synergistic GH release — the gold standard research combination (Teichman et al., 2006)

Sermorelin

Sermorelin is the first 29 amino acids of native GHRH without the stabilizing substitutions of CJC-1295:

• Half-life: ~10-20 minutes (shorter than CJC-1295)
• FDA history: Previously FDA-approved as Geref for GH deficiency diagnosis (discontinued commercially, not for safety)
• Key advantage: The most physiological GHRH analog — identical to the bioactive fragment of native GHRH
• Best for: Research requiring the closest approximation to natural GHRH stimulation

Tesamorelin

Tesamorelin is the only currently FDA-approved GHRH analog:

• Structure: 44-amino acid GHRH analog with trans-3-hexenoic acid modification
• FDA-approved: Egrifta, for HIV-associated lipodystrophy (visceral fat reduction)
• Unique data: Clinical trials showing ~15% visceral fat reduction AND improved cognitive function in MCI subjects
• Key advantage: Highest evidence quality of any GH secretagogue — Phase III RCT data, FDA review

GHRPs: Amplifying the Release

Growth hormone-releasing peptides (GHRPs) act on the ghrelin receptor (GHS-R1a) to stimulate GH release through a pathway independent of GHRH:

Ipamorelin

Ipamorelin is the most selective GHRP:

• Selectivity: Stimulates GH release with minimal effects on cortisol, prolactin, and ACTH — the cleanest GHRP profile
• Desensitization resistance: More resistant to GHS-R1a tachyphylaxis than other GHRPs
• Key advantage: Selectivity makes it ideal for long-term GH research where cortisol/prolactin confounding must be minimized
• Best combined with: CJC-1295 (GHRH + GHRP synergy) (Raun et al., 1998)

Hexarelin

Hexarelin is among the most potent GHRPs for acute GH release:

• Potency: Produces larger GH pulses than Ipamorelin
• Less selective: Significantly raises cortisol, prolactin, and ACTH
• Desensitization: More prone to tachyphylaxis with chronic use
• Unique feature: Cardioprotective effects through cardiac GHS-R1a receptors, independent of GH

GHRP-6

• Appetite stimulation: The strongest appetite-increasing GHRP due to potent ghrelin receptor activation
• Less selective: Raises cortisol and prolactin
• Historical significance: One of the first synthetic GHRPs developed

GHRP-2

• Potency: Slightly more potent than GHRP-6 for GH release
• Moderate selectivity: Less cortisol/prolactin elevation than Hexarelin but more than Ipamorelin
• Appetite: Moderate appetite increase (less than GHRP-6)

Complete GH Secretagogue Comparison

The GHRH + GHRP Synergy Explained

The single most important concept in GH secretagogue research is the synergy between GHRH and GHRP pathways:

• GHRH (CJC-1295): Activates cAMP/PKA signaling in somatotrophs ? GH gene transcription + GH release priming
• GHRP (Ipamorelin): Activates IP3/PKC signaling ? direct GH release trigger + somatostatin suppression
• Combined: Two different signaling cascades on the same cell, plus somatostatin removal, produces 5-10x greater GH release than either alone

This is why the CJC-1295 + Ipamorelin combination is considered the gold standard for GH research.

Age-Related GH Decline (Somatopause)

GH secretion declines approximately 14% per decade after age 30. By age 60, GH output may be 20-50% of young adult levels. This “somatopause” contributes to:

• Increased visceral fat and decreased lean mass
• Reduced bone mineral density
• Thinner skin and slower wound healing
• Decreased exercise capacity and recovery
• Impaired cognitive function

GH secretagogues aim to restore physiological GH levels by stimulating the body’s own pituitary to produce more GH, rather than replacing it with exogenous GH.

Frequently Asked Questions

Which GH secretagogue is best for beginners?

The CJC-1295 + Ipamorelin combination is the most researched and well-characterized GH secretagogue stack. Ipamorelin’s selectivity minimizes side effects, and CJC-1295 provides the GHRH stimulus for synergy.

Are GH secretagogues better than exogenous GH?

GH secretagogues stimulate endogenous GH production with preserved feedback regulation, producing physiological GH patterns. Exogenous GH replacement provides supraphysiological levels that bypass feedback, potentially causing more side effects. For research seeking to optimize (not maximize) GH levels, secretagogues offer a more physiological approach.

How do you monitor GH secretagogue response?

IGF-1 blood levels are the standard biomarker for GH secretagogue efficacy. IGF-1 has a longer half-life than GH and provides a more stable indicator of GH axis activation. GH stimulation tests (measuring GH response to a test dose) can assess pituitary responsiveness.

Conclusion

Growth hormone secretagogues offer a sophisticated approach to GH axis research, from physiological GHRH stimulation (CJC-1295, Sermorelin, Tesamorelin) to ghrelin receptor amplification (Ipamorelin). The GHRH + GHRP synergy principle remains the foundation of GH research protocol design. Browse our research peptides and research guides.